C03994: Therapeutic for Ocular-related DiseasesNovelty:
A method of prophylactically or therapeutically treating an ocular disorder associated with abnormal neovascularization.
Value Proposition:
An overwhelming majority of the worlds population will experience some degree of vision loss in their lifetime, with the leading cause being ocular disorders. Ocular-related disorders, while often not life threatening, can be severely debilitating and require massive life-style changes. For many of the numerous ocular-disorders that exist, there are currently no effective therapeutic options. The few treatments that do exist can cause blind spot and almost all have been found to be equivalent to no treatment at all. This technology provides materials and methods for prophylactically and therapeutically treating ocular-related disorders associated with neovascularization. Advantages include:
• Highly selective in destroying endothelial cells associated with new vascular structures, without harming existing vasculature within the eye
• Applicable to a an array of ocular disease states
• Safe and effective
Technical Details:
Johns Hopkins researchers have developed a method of prophylactically and therapeutically treating ocular neovascularization by directly administering a therapeutic factor or nucleic acid sequence encoding a therapeutic factor to the eye to selectively induce apoptosis of endothelial cells associated with neovascularization. The therapeutic factor contains at least one inhibitor of angiogenesis and/or at least one neurotrophic factor to an ocular cell.
Looking for Partners:
To develop and commercialize the technology for the treatment of ocular-related disorders.
Stage of Development:
Pre-clinical
Data Availability:
In vitro data and in vivo data available
Publications/Associated Cases:
1. Hum Gene Ther. 2005 Apr;16(4):473-8
2. Gene Ther. 2003 Apr;10(8):637-46
